|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ,
Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et
al: Rethinking ovarian cancer II: Reducing mortality from
high-grade serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heo JH, Song JY, Jeong JY, Kim G, Kim TH,
Kang H, Kwon AY and An HJ: Fibulin-5 is a tumour suppressor
inhibiting cell migration and invasion in ovarian cancer. J Clin
Pathol. 69:109–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Timpl R, Sasaki T, Kostka G and Chu ML:
Fibulins: A versatile family of extracellular matrix proteins. Nat
Rev Mol Cell Biol. 4:479–489. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gallagher WM, Currid CA and Whelan LC:
Fibulins and cancer: Friend or foe? Trends Mol Med. 11:336–340.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Obaya AJ, Rua S, Moncada-Pazos A and Cal
S: The dual role of fibulins in tumorigenesis. Cancer Lett.
325:132–138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yanagisawa H, Schluterman MK and Brekken
RA: Fibulin-5, an integrin-binding matricellular protein: Its
function in development and disease. J Cell Commun Signal.
3:337–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Vega S, Iwamoto T and Yamada Y:
Fibulins: Multiple roles in matrix structures and tissue functions.
Cell Mol Life Sci. 66:1890–1902. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Albig AR and Schiemann WP: Fibulin-5
function during tumorigenesis. Future Oncol. 1:23–35. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Song X, Yue W, Chen D, Yu J, Yao Z
and Zhang L: Fibulin-5 inhibits Wnt/β-catenin signaling in lung
cancer. Oncotarget. 6:150222015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mohamedi Y, Fontanil T, Solares L,
Garcia-Suárez O, García- Piqueras J, Vega JA, Cal S and Obaya AJ:
Fibulin-5 downregulates Ki-67 and inhibits proliferation and
invasion of breast cancer cells. Int J Oncol. 48:1447–1456. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tu K, Dou C, Zheng X, Li C, Yang W, Yao Y
and Liu Q: Fibulin-5 inhibits hepatocellular carcinoma cell
migration and invasion by down-regulating matrix
metalloproteinase-7 expression. BMC Cancer. 14:9382014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yue W, Sun Q, Landreneau R, Wu C,
Siegfried JM, Yu J and Zhang L: Fibulin-5 suppresses lung cancer
invasion by inhibiting matrix metalloproteinase-7 expression.
Cancer Res. 69:6339–6346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto
T, Kato S and Miyazono K: Modulation of microRNA processing by p53.
Nature. 460:529–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ranganathan K and Sivasankar V:
MicroRNAs-biology and clinical applications. J Oral Maxillofac
Pathol. 18:229–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Svoronos AA, Engelman DM and Slack FJ:
OncomiR or tumor suppressor? The duplicity of microRNAs in cancer.
Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo D, Li Y, Chen Y, Zhang D, Wang X, Lu
G, Ren M, Lu X and He S: DANCR promotes HCC progression and
regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1
pathway. Cell Prolif. 52:e126282019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li L and Luo Z: Dysregulated miR-27a-3p
promotes nasopharyngeal carcinoma cell proliferation and migration
by targeting Mapk10. Oncol Rep. 37:2679–2687. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng G, Xun W, Wei K, Yang Y and Shen H:
MicroRNA-27a-3p regulates epithelial to mesenchymal transition via
targeting YAP1 in oral squamous cell carcinoma cells. Oncol Rep.
36:1475–1482. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamauchi Y, Tsuruga E, Nakashima K, Sawa Y
and Ishikawa H: Fibulin-4 and-5, but not fibulin-2, are associated
with tropoelastin deposition in elastin-producing cell culture.
Acta Histochem Cytochem. 43:131–138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar
|
|
25
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36((Database Issue)): D149–D153. 2008.PubMed/NCBI
|
|
26
|
Li E, Han K and Zhou X: microRNA-27a-3p
down-regulation inhibits malignant biological behaviors of ovarian
cancer by targeting BTG1. Open Med (Wars). 14:577–585. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Z, Ji G, Wu Q, Feng S, Zhao Y, Cao Z
and Tao C: Integrated microarray meta-analysis identifies miRNA-27a
as an oncogene in ovarian cancer by inhibiting FOXO1. Life Sci.
210:263–270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA;
Gynecologic Oncology Group, : Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chan JK, Cheung MK, Husain A, Teng NN,
West D, Whittemore AS, Berek JS and Osann K: Patterns and progress
in ovarian cancer over 14 years. Obstet Gynecol. 108:521–528. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kurman RJ: Origin and molecular
pathogenesis of ovarian high- grade serous carcinoma. Ann Oncol. 24
(Suppl 10):x16–x21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mezzanzanica D: Ovarian cancer: A
molecularly insidious disease. Chin J Cancer. 34:1–3. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schiemann WP, Blobe GC, Kalume DE, Pandey
A and Lodish HF: Context-specific effects of fibulin-5 (DANCE/EVEC)
on cell proliferation, motility, and invasion. Fibulin-5 is induced
by transforming growth factor-beta and affects protein kinase
cascades. J Biol Chem. 277:27367–27377. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li H, Guan H, Guo Y, Liang W, Liu L, He X,
Ke W, Cao X, Xiao H and Li Y: CITED1 promotes proliferation of
papillary thyroid cancer cells via the regulation of p21 and p27.
Cell Biosci. 8:572018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee YH, Albig AR, Regner M, Schiemann BJ
and Schiemann WP: Fibulin-5 initiates epithelial-mesenchymal
transition (EMT) and enhances EMT induced by TGF-beta in mammary
epithelial cells via a MMP-dependent mechanism. Carcinogenesis.
29:2243–2251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang W, Chen H, Gao W, Wang S, Wu K, Lu C,
Luo X, Li L and Yu C: Girdin interaction with vimentin induces EMT
and promotes the growth and metastasis of pancreatic ductal
adenocarcinoma. Oncol Rep. 44:637–649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chong GO, Jeon H-S, Han HS, Son JW, Lee
YH, Hong DG, Lee YS and Cho YL: Differential microRNA expression
profiles in primary and recurrent epithelial ovarian cancer.
Anticancer Res. 35:2611–2617. 2015.PubMed/NCBI
|
|
39
|
Llauradó M, Majem B, Altadill T, Lanau L,
Castellví J, Sánchez-Iglesias JL, Cabrera S, De la Torre J,
Díaz-Feijoo B, Pérez-Benavente A, et al: MicroRNAs as prognostic
markers in ovarian cancer. Mol Cell Endocrinol. 390:73–84. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K,
Xu H and Jiang S: miR-24-3p and miR-27a-3p promote cell
proliferation in glioma cells via cooperative regulation of MXI1.
Int J Oncol. 42:757–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
